K. Margolis

Learn More
BACKGROUND The Women's Health Initiative (WHI) Data Safety and Monitoring Board terminated the trial arm of the estrogen plus progestin combined hormone therapy early after observing an excess of harm relative to benefit of this therapy. METHODS To learn how postmenopausal hormone therapy (PMT) use in a community setting was affected by the WHI results,(More)
Phosphacan is a chondroitin sulfate proteoglycan produced by glial cells in the central nervous system, and represents the extracellular domain of a receptor-type protein tyrosine phosphatase (RPTPg'/B). We previously demonstrated that soluble phosphacan inhibited the aggregation of microbeads coated with N-CAM or Ng-CAM, and have now found that soluble(More)
Given the high costs of conducting a drug-response trial, researchers are now aiming to use retrospective analyses to conduct genome-wide association studies (GWAS) to identify underlying genetic contributions to drug-response variation. To prevent confounding results from a GWAS to investigate drug response, it is necessary to account for concomitant(More)
Although one in three women in the United States will die of heart disease, traditionally coronary artery disease (CAD) in women has received less recognition as a public health problem than has the disease in men. To assist practicing physicians in recognizing CAD in women, this article reviews sex differences in risk factors and manifestations of CAD as(More)
  • 1